Based on this systematic review, it was determined that the administration of the HPV vaccine, compared with the control group, was not associated with a higher frequency of serious adverse events RR = 1.00; 95% CI: 0.91-1.09; 7 studies, 43,856 participants, I2: 0 %.
Con base en esta revisión sistemática se pudo establecer que, comparada con el grupo control, la administració de la vacuna para el VPH no se asoció con una mayor frecuencia de eventos adversos serios RR = 1,00; IC 95%: 0,91-1,09; 7 estudios, 43.856 participantes, I2: 0 %.